{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:33:24Z","timestamp":1784349204622,"version":"3.55.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ezetimibe is a widely used medication to reduce the plasma cholesterol level, particularly low-density lipoprotein level. However, its impact on cancer remains controversial. Here, its impacts on risks of various types of cancers were meta-analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">PubMed<\/jats:italic> and <jats:italic toggle=\"yes\">Cochrane Library<\/jats:italic> electronic databases were searched and randomized controlled trials with followed up for at least 24\u2009weeks were selected and included. The experimental group was defined as those patients treated with ezetimibe alone or with other medications, and the control group was defined as those who received a placebo or the matched medication. The number of new cancer cases or cancer-related deaths was extracted. Statistical analysis was performed using Review Manager (version 5.3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nine trials enrolling 35\u2009222 patients were included in the analyses. Compared with the control group, ezetimibe increased the number of new intestine cancer patients [relative risk (RR), 1.30; 95% confidence interval (CI), 1.02\u20131.67; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.03] and had a trend to increase the number of new breast cancer patients (RR, 1.39; 95% CI, 0.98\u20131.98; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.07). There was no significant difference in new hepatobiliary cancer, prostate cancer, skin cancer or cancer of other sites. Ezetimibe did not significantly increase the risk of new cancer in total (RR, 1.03; 95% CI, 0.96\u20131.11; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.38), cancer-related death (RR, 1.11; 95% CI, 0.98\u20131.26; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.10) or cancer events (RR, 1.04; 95% CI, 0.97\u20131.12; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.30). In terms of lipid-lowering effect, ezetimibe significantly reduced total cholesterol and low-density lipoprotein cholesterol, increased high-density lipoprotein cholesterol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Ezetimibe may increase the risk of intestine cancer and has a trend of increasing the risk of breast cancer. There is no evidence to support that it increases or decreases the risk of other types.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000750","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:01:05Z","timestamp":1648638065000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Impacts of ezetimibe on risks of various types of cancers: a meta-analysis and systematic review"],"prefix":"10.1097","volume":"32","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine"},{"name":"Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research (Hebei), Shijiazhuang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"bqab095","DOI":"10.1210\/endocr\/bqab095","article-title":"The cholesterol metabolite 27HC increases secretion of extracellular vesicles which promote breast cancer progression.","volume":"162","author":"Baek","year":"2021","journal-title":"Endocrinology"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"e23445","DOI":"10.1097\/MD.0000000000023445","article-title":"Prevalence and management of hypercholesterolemia in France, the Esteban observational study.","volume":"99","author":"Blacher","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.","volume":"168","author":"Blazing","year":"2014","journal-title":"Am Heart J"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.3390\/cells9081819","article-title":"Cholesterol and mevalonate: two metabolites involved in breast cancer progression and drug resistance through the ERR\u03b1 pathway.","volume":"9","author":"Brindisi","year":"2020","journal-title":"Cells"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20250527","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/ncomms2835","article-title":"Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties.","volume":"4","author":"de Medina","year":"2013","journal-title":"Nat Commun"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-019-0945-5","article-title":"Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death.","volume":"567","author":"Garcia-Bermudez","year":"2019","journal-title":"Nature"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.7150\/jca.54637","article-title":"Impact of cholesterol-pathways on breast cancer development, a metabolic landscape.","volume":"12","author":"Gonz\u00e1lez-Ortiz","year":"2021","journal-title":"J Cancer"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12885-015-1230-0","article-title":"NPC1L1 knockout protects against colitis-associated tumorigenesis in mice.","volume":"15","author":"He","year":"2015","journal-title":"BMC Cancer"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"e22894","DOI":"10.1097\/MD.0000000000022894","article-title":"Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: a meta-analysis.","volume":"99","author":"Jia","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"e180713","DOI":"10.1001\/jamanetworkopen.2018.0713","article-title":"Temporal associations of alcohol and tobacco consumption with cancer mortality.","volume":"1","author":"Jiang","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/2211-5463.13137","article-title":"SREBP1\/FASN\/cholesterol axis facilitates radioresistance in colorectal cancer.","volume":"11","author":"Jin","year":"2021","journal-title":"FEBS Open Bio"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2020.09.009","article-title":"Reduction of squalene epoxidase by cholesterol accumulation accelerates colorectal cancer progression and metastasis.","volume":"160","author":"Jun","year":"2021","journal-title":"Gastroenterology"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/ije\/dyx096","article-title":"Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.","volume":"46","author":"Kobber\u00f8 Lauridsen","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248412445506","article-title":"Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.","volume":"18","author":"Kouvelos","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.","volume":"47","author":"Landray","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R24-20250527","first-page":"975","article-title":"The association and joint effect of serum cholesterol, glycemic status with the risk of incident cancer among middle-aged and elderly population in china cardiometabolic disease and cancer cohort (4C)-study.","volume":"10","author":"Li","year":"2020","journal-title":"Am J Cancer Res"},{"key":"R25-20250527","first-page":"149","article-title":"Paraneoplastic dermatomyositis accompanying nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"28","author":"Liang","year":"2020","journal-title":"Hong Kong J Dermatol"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"41582","DOI":"10.18632\/oncotarget.15078","article-title":"Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial.","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"114654","DOI":"10.1016\/j.bcp.2021.114654","article-title":"Lipoproteins and cancer: the role of HDL-C, LDL-C, and cholesterol-lowering drugs.","volume":"196","author":"Patel","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials.","volume":"359","author":"Peto","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s12885-021-08433-z","article-title":"Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).","volume":"21","author":"Rusmaully","year":"2021","journal-title":"BMC Cancer"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-017-0508-4","article-title":"Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.","volume":"16","author":"Sakamoto","year":"2017","journal-title":"Lipids Health Dis"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021.","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.bbrc.2019.02.123","article-title":"Cholesterol regulates cell proliferation and apoptosis of colorectal cancer by modulating miR-33a-PIM3 pathway.","volume":"511","author":"Wang","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/cam4.1987","article-title":"Correlation between immune signature and high-density lipoprotein cholesterol level in stage II\/III colorectal cancer.","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:02:22Z","timestamp":1748361742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000750","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}